Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases
Archives of Medical Research · 2025
DOI: 10.1016/j.arcmed.2024.103141 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Archives of Medical Research, 2025. Verfasst von Paula María Corbalan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Reumatología, Hospital Angel Cruz Padilla, Tucumán, Argentina. Hauptthemen laut MEDLINE: COVID-19 Vaccines, Immunity, Humoral, Rheumatic Diseases, COVID-19. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patients with autoimmune rheumatic diseases (ARD) are at increased risk of infection due to their impaired immune response, which also reduces vaccination efficacy. Although several studies have evaluated the serological response to SARS-CoV-2 mRNA-based vaccines in patients with ARD, limited information on immune responses to other vaccination platforms is available. AIMS: This observational prospective study aims to investigate the humoral immune response to different SARS-CoV-2 vaccines in patients with ARD. METHODS: Total 66 patients with ARD who were scheduled to receive any SARS-CoV-2 vaccine (Gam-COVID-Vac; AZD1222; BBIBP-CorV; mRNA-1273; BNT162b2 and Ad5-nCoV) were enrolled in the study. We analyzed the humoral immune response elicited against the spike receptor-binding-domain (RBD) of SARS-CoV-2 at 0 and 14 ± 2 d after the first vaccine dose and at 0 ± 1, 21-45, and 180 d after the second one. Titers were also measured in patients who received an additional dose of vaccine. RESULTS: After the second dose of the vaccine, 70.5% experienced seroconversion. The type of vaccine affected serological responses. BBIBP-CorV resulted in lower seroconversion rates, while mixed vaccinations increased anti-RBD titers. Other factors impacting seroconversion were higher prednisone doses, biological therapy, and hypertension. Patients treated with Rituximab had the lowest seroconversion rate. Regression analysis revealed an 89.0% lower probability of seroconversion for BBIBP-CorV recipients and an 88.0% lower probability for those with hypertension. An additional dose increased seroconversion to 85.7%. CONCLUSIONS: Two-dose vaccination schemes exhibited a 70.5% seroconversion rate to the SARS-CoV-2 vaccine. An additional dose increased this rate to 85.0%. Reduced humoral immune responses were associated with BBIBP-CorV, prednisone higher doses, and biological therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Reumatología, Hospital Angel Cruz Padilla, Tucumán, Argentina.
- Instituto de Investigación en Medicina Molecular y Celular Aplicada, Universidad Nacional de Tucumán, Consejo Nacional de Investigaciones Científicas y Técnicas, Sistema Provincial de Salud, Tucumán, Argentina.
- Centro de Referencia para Lactobacilos, Consejo Nacional de Investigaciones Científicas y Técnicas, Tucumán, Argentina.
- Instituto de Investigación en Medicina Molecular y Celular Aplicada, Universidad Nacional de Tucumán, Consejo Nacional de Investigaciones Científicas y Técnicas, Sistema Provincial de Salud, Tucumán, Argentina. Electron…
Zitieren
APA
Corbalan, P. M., Tomas-Grau, R. H., Pera, M., Ploper, D., Espasa, G. V., Cazorla, S. I., Leguizamón, M. L., Pingitore, E. V., Barbaglia, A. L., Maldonado-Galdeano, C., Bertolaccini, M. C., Soliz-Santander, S. E., Lucero, L. G., Ávila, C. L., Chehín, R. N., Sueldo, H. R., Socias, S. B., & Bellomio, V. I. (2025). Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases. Archives of Medical Research. https://doi.org/10.1016/j.arcmed.2024.103141
Vancouver
Corbalan PM, Tomas-Grau RH, Pera M, Ploper D, Espasa GV, Cazorla SI, et al. Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases. Archives of Medical Research. 2025. doi:10.1016/j.arcmed.2024.103141
BibTeX
@article{Corbalan2025,
author = {Corbalan, Paula María and Tomas-Grau, Rodrigo Hernán and Pera, Mariana and Ploper, Diego and Espasa, Gabriela Vanesa and Cazorla, Silvia Inés and Leguizamón, María Lilia and Pingitore, Esteban Vera and Barbaglia, Ana Lucía and Maldonado-Galdeano, Carolina and Bertolaccini, María Constanza and Soliz-Santander, Silvana Estefanía and Lucero, Luciana González and Ávila, César Luis and Chehín, Rosana Nieves and Sueldo, Héctor Raúl and Socias, Sergio Benjamín and Bellomio, Verónica Inés},
title = {Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases},
journal = {Archives of Medical Research},
year = {2025},
doi = {10.1016/j.arcmed.2024.103141}
}
EUVIMED